Boston Scientific gets FDA OK for Taxus in MRI

Interventional device manufacturer Boston Scientific of Natick, MA, reported that the Food and Drug Administration has approved enhancements to the directions for use (DFU) of its Taxus Express2 paclitaxel-eluting coronary stent system, indicating that patients receiving the stent systems may safely undergo an MRI immediately following implantation.

The company claimed that Taxus is the first drug-eluting stent to receive approval for immediate postprocedure MRI. Boston Scientific's Express2 stent system also received approval for immediate MRI exams, according to the company.

Patients receiving coronary stents have typically been required to wait approximately two months before receiving an MRI, Boston Scientific said.

By staff writers
April 5, 2005

Related Reading

Boston Scientific loses stent verdict, March 25, 2005

Boston Scientific continues robust growth, February 1, 2005

Court issues judgment in stent patent dispute, January 6, 2005

Boston Scientific provides tsunami aid, December 31, 2004

Boston Scientific to acquire AST, December 17, 2004

Copyright © 2005

Page 1 of 180
Next Page